© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
July 01, 2020
The fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase (Phesgo; Genentech) can be administered subcutaneously for patients with HER2-positive breast cancer.
June 26, 2020
Today, pharmacists are banding together to “eliminate racism, discrimination, injustice, and the marginalization of individuals within the profession.”
June 11, 2020
An exploratory analysis of 2 phase 3 trials evaluating ribociclib (Kisqali, Novartis) plus endocrine therapy in advanced breast cancer showed positive results.
June 10, 2020
Oncology pharmacy practitioners highlight challenges amid the pandemic, such as limited access to personal protective equipment and essential medications.
June 08, 2020
The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.
June 01, 2020
Officials with the FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
May 30, 2020
A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results.
Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.
May 29, 2020
The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.
An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.